N
SPRO icon

Nuveen’s Spero Therapeutics SPRO Stock Holding History

Nuveen’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60,598
Closed -$516K – 3463
2022
Q1 		$516K Hold
60,598
– – ﹤0.01% 3007
2021
Q4 		$780K Sell
60,598
-10,523
-15% -$167K ﹤0.01% 2941
2021
Q3 		$1.36M Buy
71,121
+7,079
+11% +$114K ﹤0.01% 2849
2021
Q2 		$894K Sell
64,042
-308
-0.5% -$4.3K ﹤0.01% 3049
2021
Q1 		$948K Sell
64,350
-18,596
-22% -$327K ﹤0.01% 2901
2020
Q4 		$1.61M Buy
82,946
+31,982
+63% +$499K ﹤0.01% 2616
2020
Q3 		$569K Sell
50,964
-13,599
-21% -$161K ﹤0.01% 2910
2020
Q2 		$873K Buy
64,563
+20,510
+47% +$230K ﹤0.01% 2672
2020
Q1 		$356K Buy
44,053
+5,656
+15% +$49.9K ﹤0.01% 2887
2019
Q4 		$369K Sell
38,397
-5,495
-13% -$59.3K ﹤0.01% 2963
2019
Q3 		$465K Buy
43,892
+6,416
+17% +$67.6K ﹤0.01% 2969
2019
Q2 		$431K Buy
+37,476
New +$451K ﹤0.01% 3053

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen's SPRO Position: Q2 2022 in Review

Nuveen sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 60,598 shares — an estimated $516K sold.

Nuveen first reported a position in SPRO in Q2 2019 and held it in 12 quarters. The position peaked at $1.61M in Q4 2020. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Nuveen reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 60,598 Spero Therapeutics shares in Q2 2022, an estimated $516K.
  • Nuveen first reported a position in Spero Therapeutics in Q2 2019 and held it in 12 quarters.
  • Nuveen's Spero Therapeutics position peaked at $1.61M in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.